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Hypoxia occurs in cancer, prolonged exercise, and long-term ischemia with durations of several hours or more, and the hypoxia-inducible factor 1
(HIF1) pathway response to these conditions differs from responses to transient hypoxia. We used computational modeling, validated by experiments, to
gain a quantitative, temporal understanding of the mechanisms driving HIF1 response. To test the hypothesis that HIF1α protein levels during chronic
hypoxia are tightly regulated by a series of molecular feedbacks, we took into account protein synthesis and product inhibition, and analyzed HIF1 system
changes in response to hypoxic exposures beyond 3 to 4 h.We showhow three autocrine feedback loops together regulateHIF1α hydroxylation in different
microenvironments. Results demonstrate that prolyl hydroxylase, succinate and HIF1α feedback determine intracellular HIF1α levels over the course of
hours to days. Themodel provides quantitative insight critical for characterizingmolecular mechanisms underlying a cell's response to long-term hypoxia.
© 2007 Elsevier B.V. All rights reserved.Keywords: Angiogenesis; Cancer; Chronic hypoxia; Computational modeling; Ischemia; Prolonged exercise1. Introduction
Hypoxia occurs in cancer, prolonged exercise, and long-term
ischemia with durations of several hours or more. Under these
conditions, the threshold of hypoxic response changes. Mam-
malian cells exposed to chronic hypoxia (5% oxygen), and then
exposed to a lower level of oxygen (0.5%) are capable of
showing a response consistent with acute hypoxia, but
attenuated [1]. In addition, mammals in normoxia, with prior
chronic hypoxic exposure, exhibit an augmented ventilatory
response to subsequent acute hypoxia [2]. Furthermore, hypoxic
preconditioning contributes to a limited hypoxic response in
reoxygenated cells [3] and shows protective effects in mammals
exposed to ischemia [4]. Hydroxylation enzyme synthesis and
its effect on degradation of hypoxia inducible factor 1α (HIF1α)
contribute to this setpoint adjustment [1,3,5,6]. Here we sought
to explore in depth the dynamics of this process, and test theAbbreviations: HIF, hypoxia-inducible factor; PHD, prolyl hydroxylase
domain; SC, succinate; SDH, succinate dehydrogenase; VHL, von Hippel-Lindau;
Asc, ascorbate; 2OG, 2-oxoglutarate; ARNT, aryl hydrocarbon receptor nuclear
translocator
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doi:10.1016/j.bbamcr.2007.07.004hypothesis that three feedback loops (HIF1α synthesis, prolyl
hydroxylase synthesis and succinate (SC) production inhibition)
work in combination to tightly regulate the effects of chronic
hypoxia via control of HIF1α degradation.
HIF1 is a heterodimer, comprised of subunits HIF1α and
HIF1β. The beta subunit is constitutively expressed in cells.
Expression of the alpha subunit may be induced by a number of
pathways, and its degradation is highly sensitive to O2 levels.
Called a ‘master switch for hypoxic gene expression’ [7,8],
intracellular HIF1α in normoxia is experimentally undetectable;
during hypoxia, it rapidly accumulates in the cell nucleus, and
triggers gene expression. In normoxia, enzymes called prolyl
hydroxylase domains (PHDs) react with HIF1α (Fig. 1A). PHDs
hydroxylate HIF1α at the HIF1α protein's two proline residue
sites Pro-402 and Pro-564, in the oxygen-dependent degradation
domain. The activity of PHDs depends on the amount of oxygen
available. One of the PHD isoforms, PHD2, is the most abundant
prolyl hydroxylase isoform in the cell cytoplasm during
normoxia; it has been credited as a controller of steady-state
HIF1α concentrations under these conditions in a range of cell
types [9,10]. Following the reaction with PHD, the hydroxylated
HIF1α is free to bind to a von Hippel-Lindau (VHL) ubiquitin
ligase complex (VHL in this paper refers to the protein product
Fig. 1. The HIF1 pathway in normoxia (A) and hypoxia (B). (A) HIF1α hydroxylation and degradation in the presence of oxygen involves: (1) the independent
oxidation–reduction reactions of ascorbate (Asc) and iron (Fe); (2) and (3) prolyl hydroxylase 2 (PHD2) binding to Fe, 2-oxoglutarate (2OG), and O2; (4a) PHD2
hydroxylation of HIF1α, involving (4b) production of the by-products succinate and CO2; (5) unbound hydroxylated HIF1αmoving in the cell cytoplasm; (6) the von
Hippel-Lindau (VHL)–Elongin B (EB)–Elongin C (EC) complex ubiquitinating HIF1α; and (7) HIF1α degradation. A color change in HIF1α indicates addition of a
hydroxyl group. (B) In hypoxia, HIF1α enters the nucleus, where hydroxylation, but no degradation occurs. (1) and (2) PHD2 binding to Fe, 2OG and Asc, but not O2.
(3) The protein inhibitor of growth 4 (ING4) binding to PHD2 may regulate HIF1α transcriptional activity and (4) block HIF1α-HIF1β binding. (5) When HIF1α-HIF1β
binding occurs, the HIF1 dimer can transcriptionally activate genes at the hypoxia response element (HRE) site. Activated HIF1-dependent genes, where protein levels are
upregulated, include PHD2 (6a) and HIF1α (6b). (C) Schematic of a potential mechanism for adaptation during chronic hypoxia. Three feedback loops govern HIF1α
hydroxylation; HIF1α synthesis; prolyl hydroxylase 2 (PHD2) synthesis; and succinate production inhibition. Succinate is also a metabolic product of the TCA cycle.
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HIF1α for proteasomal destruction.
In hypoxia, HIF1α escapes hydroxylation, accumulates and enters
the cell nucleus, where it binds to HIF1β (known also as ARNT, aryl
hydrocarbon receptor nuclear translocator) (Fig. 1B). The HIF1α-
HIF1β dimer transcriptionally activates a host of genes, including
those encoding for angiogenic growth factors [11–13]; erythropoietin
[14]; and proteins critical to glycolysis [15]. Through transcriptional
regulation of these genes,HIF1 contributes to angiogenesis and altered
cellmetabolism— critical processes that facilitate a tumor's growth or
help extend muscle contraction, for example. HIF1 and its related
pathways are attractive therapeutic targets in cancer and ischemia
[16,17], and aremeasures of enhanced exercise response [18]. Specificto this work, HIF1 regulation offers a way to alter physiological
responses to the chronic ischemia found in peripheral vascular disease
and coronary artery disease [19] and the long-term, heterogeneous
hypoxia found in different tumors [20,21].
A balance of HIF1α levels and HIF1α activity seems
necessary to achieve health [22,23]. This is particularly relevant
in conditions of chronic hypoxia, where continued upregulation
of hypoxia-induced genes may induce or predispose individuals
to malignancy [24]. In vitro studies have shown how the hypoxic
response varies based on vascular microenvironment [25,26].
Exposure to low levels of oxygen for over 3 h can alter HIF1α
hydroxylation, and thereby HIF1 signaling, through multiple
pathways.
Table 1
Model variables and their abbreviations
Variable Abbreviation
Concentration of A [A]
AEB Binding of A and B
Ascorbate Asc
Iron Fe2+, Fe3+
Prolyl hydroxylases PHD2
Hypoxia inducible factor hydroxylated HIF1αh
HIF1α unhydroxylated HIF1α
von Hippel Lindau VHL
Succinate SC
Succinate dehydrogenase SDH
Carbon dioxide CO2
2-oxoglutarate 2OG
Oxygen O2
Elongin B EB
Elongin C EC
Cullins 2 Cul2
Hydrogen peroxide H2O2
Dehydro-ascorbate dehydroAsc
Start time for HIF1α synthesis (h) tHIF1α
Start time for PHD2 synthesis (h) tPHD2
Reverse rate for PHD2 complex binding to HIF1α (min−1) koff,HIF1α
Reverse rate for PHD2 complex binding to HIF1α,
incorporating SC (min−1)
k′off,HIF1α
Kinetic term relating O2 to SC levels (min
−1) kSC
Production constant for HIF1α (μM min−1) kprod,HIF1α
Production constant for HIF1α (min−1) k′prod,HIF1α
Production constant for PHD2 (unitless) kprod,PHD2
Production constant for PHD2 (unitless) k′prod,PHD2(t)
Synthesis term for HIF1α (μM min−1) qprod,HIF1α
Synthesis term for PHD2 (μM min−1) qprod,PHD2
Synthesis term for PHD2 (μM min−1), case 2 q1prod,PHD2
Synthesis term for PHD2 (μM min−1), case 2 q2prod,PHD2
Table 2
Parameters and their initial values for the degradation of HIF1α in normoxia,
and accumulation of HIF1α and PHD2 in hypoxia
Constant Value Reference
[H2O2]0 0.20 μM
a [75]
[O2]0 200 μM [37]
[Fe3+]0 0 μM –
[Fe2+]0 50 μM [37]
[2OG]0 1000 μM [37]
[Asc]0 1000 μM [37]
[HIF1α]0 1 μM [37]
[PHD2]0 1 μM; 4 nM (where stated for
in vitro comparisons)
[37]
0.15 μM (calculated by model
to scale with experiment)
[5]
[SC]0 0.5 μM (0–5 mM)
b [23,36,69]
koff,HIF1α 0.7 min
−1, estimate –
k′off,HIF1α N0.7 min
−1, k′off,HIF1α=koff,HIF1α+kon,SC –
kSC 0.0001–0.1 min
−1, range explored –
kprod,HIF1α 0.01–1 μM h
−1, range explored –
k′prod,HIF1α 0.1 or 1 h
−1 –
kprod,PHD2 C3 kprod,HIF1α, unitless (relative to HIF1α synthesis)
where C3=0–1000 (fold times kprod,Hα) μM
−1·h
–
k′prod,PHD2 C4 · time, unitless (relative to HIF1α synthesis)
where C4=0.01 h
−1
[5] c
tHIF1α 3 h [5]
tPHD2 4 h [5]
Values are experimentally determined or estimated, or estimated from model
calculations as noted. All values are at 37 °C.
a Assumed, as an approximation. Range of 0.13–0.25 μM given in the cited
reference. Within this range, the effects on varying H2O2 initial concentration
on the model response are small.
b Initial intracellular concentration for succinate is not zero, but a base value
due to Krebs cycle succinate production. For the purposes of product inhibition
of the HIF1α hydroxylation, all succinate considered is formed by the
hydroxylation reaction.
c Approximate C4 value estimated from slope of curve for PHD2 protein
levels vs. time at 1% O2 from reference [6].
(1)
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levels include autocrine upregulation of HIF1α activity by HIF1α
synthesis, downregulation of HIF1α by PHD2 synthesis, and
succinate production inhibition. Knowledge of HIF1α and PHD2
synthesis comes from in vitro studies and limited in vivo
experiments showing PHD2 is HIF1-dependent and hypoxia-
inducible [3,5,27,28]. In vivo experiments in neonatal rat brain
have also shown thatHIF1α and PHD2 synthesis occur at different
times in response to hypoxic preconditioning [6]. PHD2
hydroxylation of HIF1α produces the compound succinate.
Succinate and 2-oxoglutarate (2OG), a PHD2 cofactor, act
competitively, and succinate thereby feedback inhibits the PHDs
[22,23,29]. Succinate dehydrogenase (SDH), a mitochondrial
membrane enzyme, oxidizes succinate; and inhibiting SDH can
lead to intracellular succinate levels near 0.5 mM [23]. Here, we
show how in chronic conditions, the three feedback loops can
combine to determine HIF1α hydroxylation, intracellular HIF1α
protein levels, and ultimately, intracellular hypoxic adaptation.
2. Methods
2.1. Formulation of Computational Model
The biochemical pathway model of oxygen sensing by HIF1α was introduced
elsewhere [30]. Here we extend the model by adding succinate and its associated
molecules, and further characterizing hypoxia-induced synthesis of HIF1α and
PHD2. Briefly, from a comprehensive analysis of experimental data, we representthe hydroxylation of HIF1α by PHDs and the ubiquitination of hydroxylated HIF1α
by VHL (Fig. 1A). We modeled the hydroxylation of HIF1α by PHD2 in the cell
cytoplasm. The compounds involved in binding to PHD2 in preparation for the
hydroxylation of HIF1α include iron, 2-oxoglutarate, oxygen and ascorbate (Asc).
The modified PHD2 then binds and hydroxylates HIF1α. Simultaneously, the
hydroxylation reaction produces the by-products succinate and carbon dioxide.
Hydroxylated HIF1α is recognized and ubiquitinated by VBC (VHL·Elongins BC),
the complex that includes VHL bound to Elongins B and C, Cul2 and Rbx1. Table 1
lists the compounds included in the model.
Eq. (1) describes the overall scheme of HIF1α degradation. The model includes
HIF1α hydroxylation, independent reactions of iron and ascorbate, succinate
accumulation and product inhibition (Eqs. (A1), (A2), and (A5)), PHD2 synthesis
(Eq. (A1)), HIF1α synthesis (Eq. (A2)), and the binding of HIF1α to VHL (Eqs.
(23–26) in [30]) illustrated in Fig. 1A–C.The hydroxylation reactions follow enzyme–substrate binding kinetics.
Governing equations are determined from mass balances surrounding the
substrate and the intermediate enzyme–substrate complexes. A combination of
Table 3
Tested models of HIF1α and PHD2 synthesis in chronic hypoxia
Model Value Equation Time equation begins
Case 1 qprod,HIF1α kprod;HIF1ad
½O2 
ð½O2 þC2Þ where C2=0.01 μM, unless stated otherwise tHIF1α=3 hrs
qprod,PHD2 kprod,PHD2 ·qprod,HIF1α tPHD2=4 hrs
Case 2 qprod,HIF1α kprod;HIF1ad
½O2 
ð½O2 þC2Þ where C2=0.01 μM, unless stated otherwise tHIF1α=3 hrs
qprod,PHD2 k′prod,PHD2(t) ·kprod,PHD2 ·qprod,HIF1α tPHD2=4 hrs (ends at 24 hrs)
qprod,PHD2 kprod,PHD2 ·qprod,HIF1α tPHD2=24 hrs
Case 3 qprod,HIF1α kVprod;HIF1ad ½O2 d½HIF1að½HIF1aþC1d½O2 
where C1=0.01 or 1, as stated (unitless) tHIF1α=3 hrs
qprod,PHD2 kprod,PHD2 ·qprod,HIF1α tPHD2=4 hrs
The form of each equation is estimated from experimental data on time and oxygen dependency of synthesis. Available cellular oxygen concentration [O2] is constant
throughout all model simulations, except where it is a function of succinate, as noted.
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ascorbate, 2-oxoglutarate and oxygen to PHD2, PHD2 hydroxylation of HIF, and
VHL-mediated ubiquitination. In the hydroxylation reaction of PHDs with HIF1,
we represented the binding of PHD2 with the substrates iron, 2-oxoglutarate and
oxygen, sequentially; redox reaction for ascorbate and iron are included as separate
equations [30]. These hydroxylation steps and their output were validated against
experiments previously [30]. Recent assays further confirm the relationship of
PHD2 activity and oxygen, as well as qualitatively, concur with the model on the
effects of ascorbate [31]. Model inputs are initial compound concentrations,
including cellularO2 levels (Table 2). Output is HIF1α levels in the cell cytoplasm.
The described kinetic model can be found in the , Eqs. (A1) (A2) (A3) (A4) (A5)
(A6); the complete model includes Eqs. (A1) (A2) (A3) (A4) (A5) (A6) and all
previously studied reactions [30].
Three feedback loops hypothesized to governHIF1 levels and thereby determine
the response to chronic hypoxia are represented (Fig. 1C). Production terms are
included for the synthesis of PHD2 (Eq. (A1)) and HIF1α (Eq. (A2)). Production
terms qprod,PHD2 for PHD2 in Eq. (A1) and qprod,HIF1α for HIF1α in Eq. (A2) are
nonzero only in chronic hypoxia (after 3 h, qprod,HIF1αN0; after 4 h, qprod,PHD2N0).
Estimates of these functions are based on experiments [3,5,9,32]. Product inhibition
by succinate is included by modifying the backward kinetic rates for the PHD2
complex binding to unhydroxylated HIF1α (Eq. (A3)).
2.1.1. Production of HIF1α and PHD2
Several forms for the synthesis term were tested in the model ([Table 2]). It is
possible that HIF1α synthesis has no inherent limit, except as a function of oxygen
concentration (Cases 1 and 2, Table 3); in these cases, PHD2-dependent degradation
alone causes a drop in HIF1α expression. The form of the equation in Case 1 differs
fromCase 2 by a function of time, and in Case 2, the PHD2 synthesis term until 24 h
is time-dependent, based on experimental comparisons [5].
However,a likelypossibility is thatHIF1αsynthesis itselfhasan internal limit—eitheras
a function of limited energy to synthesize newprotein or product inhibition (Case 3, Table 3).
In this case, the production can bemodeled using saturation kinetics as a function of HIF1α
levels. Case 3 represents HIF1α synthesis (and thereby PHD2 synthesis) as a non-linear
functionofO2,withamaximumat0.5%oxygen, anddecreasingsynthesis at greateror lesser
oxygen concentrations (Fig. 2A and B). For Cases 1 and 2, HIF1α synthesis increases
monotonically as a function of O2 (Fig. 2C and D). Effects on HIF1α hydroxylation of
changing the constantC1 in Case 3 are shown (Fig. 2E).
2.1.2. Succinate and product inhibition
In the hydroxylation reaction, PHD2 simultaneously splits oxygen to
hydroxylate HIF1α, and oxidizes and decarboxylates 2-oxoglutarate to succinate
(Eqs. (A1), (A2) and (A3)) [23]. Succinate and 2-oxoglutarate are also intermediate
products in the citric acid (TCA) cycle.Downregulation of succinate dehydrogenase,
an enzyme that degrades succinate, leads to intracellular succinate accumulation,
HIF1α stabilization and HIF activation [23]. Through in vitro and in vivo
experimental observations, succinate was hypothesized to act as a product inhibitor
of the PHDhydroxylation reaction of HIF1α [23,33]. Product inhibition could result
from 2-oxoglutarate (2OG) being converted into a succinic acid salt or succinate,1
and therefore not allowing 2OG to be available to the PHD2 forward hydroxylation
reaction. Inhibition could also result from a direct increase in the reverse flux.1 2OG↔ succinate semialdehyde+CO2 succinate semialdehyde+NAD(P)
++
H2O→SC+NAD(P)H.Alternately, it could result from binding of succinate to the PHD2 enzyme and
decreasing the affinity of the enzyme for HIF1α. As the mechanism or combination
of mechanisms is still being explored, we choose to represent succinate product
inhibition as changes in the reverse kinetic rate (Eq. (A5)).
Intracellular levels of succinate, while yet unknown in vivo, are anticipated
to vary widely by cell type and metabolic conditions [23,34,35]. The range of
explored initial succinate concentrations, 0–5 mM, was determined by assuming
no initial accumulation of the product for the minimum value and using in vitro
levels for the maximum ([Table 2]). The maximum value of 5 mM succinate is
from experiments exploring SDH and succinate activity, where succinate was
added to the media of HEK293 human embryonic kidney cell extracts [23] or
isolated rat liver mitochondria [36], respectively. In vivo, intracellular succinate
levels would be anticipated to be lower, even in SDH dysfunction. One in vitro
study estimated ∼500 μM succinate is produced in cells, where SDH was
inhibited [23]. A following study reported 0.1 to 1 mM succinate levels are
required to inhibit PHD activity; and it was suggested that in vivo, other factors
may sensitize PHD to small changes in succinate concentrations [29].
2.1.3. Calculation of intracellular oxygen for In Vivo analogies
Previously, it was assumed that reported in vitro O2 levels could be
converted to O2 concentration in cell culture media, and this represented
available cellular oxygen [30,37]. A more detailed analysis allows better
approximations to intracellular O2 levels and a direct analogy to in vivo
conditions. The analysis was done by applying Fick's law of diffusion to a
simulated two-dimensional cell culture layer and parameters estimated from
experiments [38–41]. A related diagram and the resulting estimates for
intracellular O2 concentrations are shown in Supplemental Fig. 1. In this
analysis, the culture medium acts as a barrier to oxygen diffusion. For
comparison to experiments, O2 levels provided in units of mmHg and
percentages were converted to micromolal units, consistent with the previous
model and as estimated in literature based on the solubility of oxygen in water
[37]; 1 μM≈0.78 mm Hg.
Constant O2 supply, refreshed media and a steady-state system were
assumed. O2 consumption by a confluent cell monolayer was estimated as
2 μmol/107 cells/h for T47D human breast cancer cell line [42]. (While
estimated as constant, this O2 consumption depends on cell line, cell size,
culture conditions, and cell confluency; a value of 4.5 μmol/107 cells/h for
MCF7 human breast adenocarcinoma line was also previously reported [43]).
With this O2 consumption rate Rmetabolic, an oxygen diffusivity through cell
culture media of Doxy =2×10
− 5 cm2/s and a height (h) of 2 mm for the cell
media layer [38], the steady-state value for O2 concentration at the cell
membrane–liquid interface Cmonolayer could be calculated for given
atmospheric O2 levels Csurface from the mass balance equation:
DoxyðCsurface  CmonolayerÞ=h Rmetabolized ¼ 0 ð2Þ
For a confluent cell layer of thickness d and cell diffusion coefficient for oxygen
Dcell, and metabolic rate Mmetabolic=Rmetabolic/d, solving the diffusion equation in
the cell layer with the boundary conditions C=Cmonolayer at x=0; and dC/dx=0 at
x=d, we obtain forCmin, the O2 concentration at the bottom of the cell layer (i.e., the
minimum oxygen concentration expected intracellularly):
Cmin ¼ C x ¼ dð Þ ¼ cmonolayer  Md
2
2Dcell
ð3Þ
Fig. 2. HIF1α synthesis in themodel as a function of time and oxygen concentrations. HIF1α synthesis term for the default model case shows howmaximumHIF1α synthesis
occurs at an intermediate oxygen level, while synthesis tapers at O2 concentrations above and below 0.5%,where k′prod,HIF1α=0.1 (A) and k′prod,HIF1α=1 (B). For the other two
cases, HIF1α synthesis increases linearly with time, and increasing oxygen concentrations. (C) kprod,HIF1α=0.1;C2=100 μM. (D) kprod,HIF1α=0.1;C2=0.01 μM. (E) Effect of
changing the term C1 in the default model, where C1 is the constant term in the synthesis equations for HIF1α or PHD2 (Table 3, Case 3).
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Dcell=10
−5 cm2/s, results are shown in Supplemental Fig. 1.
For atmospheric O2 levels above 7%, the calculated intracellular O2
concentration is linearly dependant on atmospheric oxygen, and calculations
could be directly compared to experiments [41]. For atmospheric O2 levels below
7%, the model estimated nearly anoxic intracellular levels, and experimental values
from literature were sought for comparison.
The relationship between extracellular and intracellular O2 levels at low O2
concentrations is a complex function of microenvironment, cell type, and cell
adaptation. Notably, intracellular respiration and O2 consumption decrease at
very low O2 levels. Isolated mitochondria change respiratory function at
intracellular O2 levels below 1 μM or ∼0.1% [44], while intact cells change O2-dependent metabolism at a significantly higher O2 level [45]. Respiratory
changes have been shown for platelets below O2 levels of 2.5 μM, dropping to
zero O2 consumption near 0.13 μM [46]; and for other cell types, respiratory
changes occur at O2 levels near 14–25 μM [47,48]. Furthermore, 4%
atmospheric oxygen values yielded pericellular O2 as low as 0.31% O2 [42].
The above experimental data on O2 consumption, while variable, was used to
estimate alternate possible intracellular O2 levels as a function of atmospheric O2
(Supplemental Fig. 1B, dashed lines). For atmospheric O2 levels below 7% O2,
Rmetabolic decreases as a function of limited O2, and an approximation of a
saturation curve replaces Rmetabolic in Eq. (2). Respiration rate was approximated
using a Km for oxygen of 1.8 μM, as reported for hepatocytes [49]. This
assumption of decreasing metabolism is also in agreement with the observed
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studies [50].
Overall, this analysis, showing possible minimum intracellular O2 levels with
constant andwith variableO2 consumption, provides an estimate of in vivoO2 levels
for conditions described in this paper.Where this paper refers to normoxia or∼15 to
21% O2 atmospheric levels, the approximated intracellular oxygen level is ∼9 to
15%, respectively, for an O2 consumption rate of 2 μmol/10
7 cells/h.
2.1.4. Model parameters
Default values for kinetic constants and initial conditions are shown in Table 2
with references. Ten of the kinetic terms from the original hydroxylation model and
estimated ranges for the new succinate constants are derived from experimental data.
Values for the synthesis kinetic rates (kprod,HIF1α, k′prod,HIF1α, k′prod,PHD2 and
kprod,PHD2) were explored relative to one another, and their effects on the synthesis
terms for model Cases 1–3 were compared (Supplement Fig. 2). Values for the
unknown parameters were estimated as described in a previous study [30].
2.1.5. Numerical solution
The system of nonlinear differential equations presented in Appendix I was
solved using Mathworks Matlab software. The ode23s solver, based on a modified
Rosenbrock formula, was used to find a solution for the series of seventeen
differential equations. For the time integration, the solver used adjustable time steps
with default absolute error tolerance in the solution of 10−6.3. Results
3.1. Chronic Hypoxia: HIF1α and PHD2 synthesis
HIF1α's half-life upon reoxygenation depends on duration of
hypoxic exposure. Beyond 3 h of hypoxia, synthesis of HIF1α
protein occurs [9], and PHD mRNA levels are upregulated by 4 h
(PHD2 minimally; PHD3 strongly [51]). mRNA levels increase
for HIF1α and PHD2 followed several hours later by elevated
protein expression. HIF1-dependent PHD2 protein production
becomes detectable between 4 and 8 h of hypoxia in vitro,
continuing beyond 24 h [5,52]. Fig. 3 shows the variability of
HIF1α hydroxylation under conditions of chronic hypoxia, where
a synthesis production term was added to the mass balance
equations for PHD2 and HIF1α in the model. The simulated
curves represent both the synthesis ofHIF1α and its hydroxylation
by increasing amounts of PHD2. As the in vivo levels of PHD2
relative to HIF1α are yet unknown experimentally and dependent
on cell type, computationally we tested a six order of magnitude
range in ratios to cover a significantly wide spectrum, and to
characterize all outputs. At very high ratios of PHD2 to HIF1α
synthesis (N10:0.1), all HIF1α becomes hydroxylated withinFig. 3. Quantitative effect of PHD2 and HIF1α synthesis on HIF1α hydroxylation
concentration or protein levels for each set of synthesis kinetic parameters. PHD2:HIF1
k′prod,HIF1α, (Eqs. (A1.3) and (A2.2)). (A) Model results showing the time course o
exposure of 0 to 72 h. See Supplemental Fig. 1A for the theoretical cases of no synthes
expression as a function of PHD2:HIF1α synthesis and hypoxia. (C)Model results sho
of PHD2 and HIF1α synthesis rates. Values are normalized to 1, the maximum [HIF1α
[HIF1α] per [PHD2], at different PHD2:HIF1α synthesis rates normalized to the maxi
Comparison of model results with experimental data. Time to represents the start tim
model, the equivalent estimated time was taken as 3 h, a time after any transient hypox
human embryonic kidney HEK293 cells [5] for HIF1α (E) and PHD2 (F) protein lev
shown in Supplemental Fig. 3. (G) The model was compared to experimental data on r
hydroxylation activity, after 1 h of hypoxia [5]. For the first model data points, the init
concentration at 2% O2 produced approximately half the hydroxylation activity at 20%
PHD2 expression value at 1% corresponded to 2. Model results for [PHD2]0=1 μM
expression in chronic hypoxia, across a range of cell types [32], is compared to possseveral hours. The effect on hydroxylation using closer synthesis
ratios is shown (Fig. 3A). Synthesis ratio refers to the ratio of the
values for kinetic parameters, kprod,HIF1α and kprod,PHD2, for model
cases 1 and 2, or k′prod,HIF1α and k′prod,PHD2, for model case 3. As
the PHD2:HIF1α ratio decreases, unhydroxylated HIF1α accu-
mulates (Fig. 3A). At very low ratios, there is a single peak of
HIF1α near 10–12 h, with elevatedHIF1α levels beyond 72 h; the
synthesis ratio 0.001:0.1 demonstrates this (Fig. 3A). At inter-
mediate values, where the synthesis rates approach each other
within ten-foldmagnitude, a second peak in [HIF1α]unhydroxylated is
present between ∼48 and 60 h (Fig. 3A).
In vivo, systems can adapt to chronic conditions, decreasing
HIF1α expression within days of hypoxic exposure. A balance of
HIF1α and PHD2 synthesis is a possible contributing mechanism.
The model predicts that unhydroxylated HIF1α accumulation
decreases following PHD2 synthesis of several hours, allowing
adaptation to hypoxia, and a new threshold for response to acute
hypoxic stimulus within days (Fig. 3A and B). Correspondingly, a
local minimum in [HIF1α]hydroxylated:[HIF1α]total is present
between 3.5 and 10 h of hypoxia, at the same PHD2:HIF1α
synthesis ratios (Fig. 3C). Notably, as more PHD2 is produced
after 8–12 h, the amount of unhydroxylated HIF1α increases
relative to the amount of PHD2 (Fig. 3D), and the efficacy (defined
by [HIF1αhydroxylated]/[PHD2]) of PHD2 in hydroxylating HIF1α
decreases.
3.2. Comparison with experimental data
To help confirm if the model represents well the biological
system,model outputwas compared to available experimental data
on relative protein levels of HIF1α and PHD2 during chronic
hypoxia. The computational synthesis terms accurately approxi-
mate the HIF1α and PHD2 synthesis observed in experiments
(Fig. 3E–H). The trendlines for HIF1α synthesis (Fig. 3E) and
PHD2 synthesis (Fig. 3F) follow those from in vitro experiments
with HEK293 cells exposed to chronic hypoxia of 1% O2 [5].
Notably, PHD2 and HIF1α expression are compared in the model
and experiments under hypoxic conditions (Fig. 3E and F). The
model's initial normoxic values of PHD2 and HIF1α were set as
1 μM(Fig. 3A and B), a 1:1 ratio, and changes in protein levels are
relative. Actual in vivo protein levels in normoxia vary by cell
type; and the chronic hypoxiamodel is farmore sensitive to PHD2:
HIF1α synthesis ratios than initial protein levels.. For 2A, 2B, 2E, and 2F, the y-axis values are normalized to the maximum
α synthesis in (A) and (B) and SR in (E) and (F) refer to synthesis rates kprod,PHD2:
f HIF1α accumulation as a function of PHD2:HIF1α synthesis during hypoxic
is and HIF1α synthesis without PHD2 synthesis. (B) Model predictions of PHD2
w the amount of hydroxylated [HIF1α] per total [HIF1α] for the four different sets
]hydroxylated/[HIF1α]total, for all simulations. (D)Model results for unhydroxylated
mum [HIF1α]unydroxylated/[PHD2] found for each set of rate parameters. (E and F)
e of experimental data collection, a time greater than 0 and less than 4 h. For the
ic response. The model qualitatively agrees with the experimental trends shown in
els. Experimental comparisons of the model using alternate synthesis terms are
elative PHD2 expression at different oxygen levels producing the same amount of
ial concentration of PHD2 of 0.15 μM at 1% O2 was determined by finding what
O2, as found experimentally [5]. The model results were then scaled so that the
at 1% are also shown, without scaling. (H) Experimental data on relative PHD2
ible model outputs using different parameter values.
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been fit to experimental data, this would eliminate its capability
of representing many different conditions and limit it to thespecific experiment detailed in the comparison. Model Case 2,
based on assumption of changes in PHD2 synthesis rate at 24 h,
fit the in vitro PHD data most closely. However, the saturation
Fig. 4. Quantitative effect of succinate concentrations on HIF1α hydroxylation in normoxia (A), (B) and (D) and hypoxia (B), without synthesis of PHD2 or HIF1α.
(A) The model reproduces competitive inhibition of PHD2 by succinate with respect to 2-oxoglutarate, as found in experiments [53]. If the lines are extended to zero
(infinite concentrations of 2OG limit this calculation), they intersect near the y-axis. For this calculation, the Km value used for Fe
2+ was 0.03 μM [74], and for 2OG,
was 1 μM [53], for consistency with the compared reciprocal plots [53]. [Fe2+]0=5 μM. Other kinetic parameters were kept as default values [30]. (B) HIF1α levels
during transient hypoxic or normoxic conditions, with and without SC production inhibition. (C) PHD2 levels during transient hypoxia, with and without SC product
inhibition. (D) Initial succinate levels affect the dynamics of HIF1α concentrations, by altering the last two steps in PHD2 hydroxylation. Values are normalized to the
maximum [HIF1α]hydroxylated:[PHD2] ratio at 24 h. (E) [HIF1α] to [PHD2] ratios during the first 4 h of hypoxia, and the effects of changing [SC]0:[PHD2]0, without
HIF1α or PHD2 synthesis. Values are normalized to the maximum [HIF1α]hydroxylated:[PHD2] ratio at 4 h. (F) Succinate to PHD2 ratios as a function of time and initial
concentrations. Below a [SC]0:[PHD2]0 ratio of 0.05:1, the curve for [SC]0:[PHD2]0 follows saturation kinetics (a). Above this ratio, there is a minimum present (b).
As the initial concentration ratios increase above 5:1, the [SC]/[PHD2] ratio becomes approximately constant.
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3 offered a better representation of the underlying biology (Eqs.
(A1.3) and (A2.2)), and this case was used as the default model.
The value of k′prod,HIF1α=0.1 h
−1 was chosen throughout theFigures using Case 3, as this was the rate that approximated
experimental curves (Fig. 3E), and it was low enough to give
visibly distinct changes in [HIF1α]unhydroxylated when compared
with the range of PHD2 synthesis rates explored (Fig. 3F). As a
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required to produce the same degree of HIF1α hydroxylation
during different levels of transient hypoxia agrees well with
experiments (Fig. 3G). The model also was tested to ensure that
it could account for experimentally observed PHD2 induction
across numerous cell lines during 16 h of hypoxic exposure
(0.5%) (Fig. 3H). Qualitatively, the model agrees also with the
findings that hypoxic preconditioning (cultured in 5% O2 for
4 weeks) of mouse clonal hippocampal HT22 cells exposed to
0.5% O2 leads to increased HIF1α, at an expression level lower
than cells cultured in normoxia and then exposed to 0.5%O2 [1].
The model might predict this to be the case, as the normoxic
levels of HIF1α approach zero within an hour [30], while the
hypoxic levels reach a new relative minimum HIF1α level after
24 h (Fig. 3A), at the same time PHD2 levels remain elevated
(Fig. 3B). Recent in vivo experiments have also confirmed the
hypoxic induction of HIF1α and PHD2, and lead to hypotheses
about PHD2's protective role in hypoxic preconditioning [6].
3.2.1. Succinate product inhibition
There are several mechanisms by which succinate (SC), and
the catalyst for its oxidative dehydrogenation, the enzyme
succinate dehydrogenase (SDH), may interfere in the PHD2
hydroxylation of HIF1α, as discussed below.We first represented
succinate through product inhibition of 2-oxoglutarate binding to
PHD2, and hence inhibition of PHD2 hydroxylation of HIF1α.
Results are shown in Figs. 4 and 5. Fig. 4 shows the cases of no
PHD2 or HIF1α synthesis. Fig. 4A, a double reciprocal plot, is
provided to show that product inhibition represented in themodel
can qualitatively reproduce experimental results [53]. With SC
production inhibition represented in the model, there is an
increase in unhydroxylated HIF1α (Fig. 4B) and decrease in free
PHD2 levels (Fig. 4C) compared to transient conditions without
succinate product inhibition. As expected in product inhibition, at
high initial succinate to PHD2 ratios (∼5:1), the amount of
HIF1α hydroxylated per PHD2 drops precipitously, in normoxia
(Fig. 4D) and acute hypoxia (Fig. 4E). This is in qualitative
agreement with recent in vitro studies on HEK 293T cells,
showing addition of SC inhibited hydroxylation.
Depending on the ratio of initial SC to PHD2 levels, the
temporal change in the normalized [SC]:[PHD2] ratio followsFig. 5. Combined effects of succinate product inhibition, PHD2 synthesis, andHIF1α
synthesis leads first to changing levels of [HIF1α]hydroxylated/[PHD2], which
eventually become linear over time. This linearly as time approaches infinity is
predicted to result from a balance between hydroxylation and succinate inhibiting
PHD2 hydroxylation, and reaching a maximum of PHD2 and HIF1α production,
inherent in the model synthesis terms. In (A) and (B), values are normalized to the
maximum [HIF1α]hydroxylated:[PHD2] ratio at 48 h, for SR=0.1:0.1. (A) Results for
[PHD2]0=1; C1=1; [SC]0=0.5 μM. (B) Results for [PHD2]0=1; C1=1;
[SC]0=5000 μM, where one peak is prominent. (C) Unhydroxylated [HIF1α], an
estimate of HIF1α protein accumulation, at different concentration ratios of [SC]0:
[PHD2]0. The time step used in (C) was 0.5min; the peaks in [HIF1α]unhydroxylated for
the [SC]0:[PHD2]0=0.5:1 and 5000:1 last for ∼1 min. The ratios of [SC]0:[PHD2]0
were chosen to represent possible ratios found in vivo in cells without a SDH or
mitochondrial deficiency ([SC]0:[PHD2]0=0.5:1 and 5:1), as well as the extreme in
vitro conditions used to mimic SDH deficiency ([SC]0:[PHD2]0=5000:1). For each
value, the predicted time course of HIF1α hydroxylation is distinct and highly
dependent on relative SC concentrations.different shaped curves, as a function of the kinetic parameters in
normoxia (Fig. 4F). The shape of the curve could be of interest, for
detailed kinetic understanding of the effects of succinate metab-
olism and feedback on the HIF1α pathway. For ratios below 0.5:1,
a saturation curve with no minimum is present (point a), while as
the ratio increases to 0.5:1, aminimum ratio occurs shortly after the
reaction begins (point b). At the higher initial concentration ratio of
5:1, beyond ∼2 h of total reaction time, the [SC]:[PHD2] ratio
steadily decreases. However, as the ratio increases further, this drop
is replaced by the relatively constant maximum values shown.
Elevated succinate levels are most likely to be present during
chronic hypoxia, such as in cancerous tissue, benign paraganglio-
Fig. 6. Succinate may affect metabolism, independent of PHD2. This is represented in the model by succinate levels signaling decreased oxygen availability, rather than
inhibiting PHD2 hydroxylation. For Fig. 5A–D, a PHD2: HIF1α synthesis ratio of 0.1:0.1 was used. For 5A, 5C, and 5D, y-axis parameters are normalized to the maximum
value for each synthesis parameter set. (A) Amount of unhydroxylated HIF1α present in chronic hypoxia at different values of the kinetic constant kSC. (B) Changes in oxygen
level are represented as a function of succinate concentration through the kinetic constant kSC. [O2]=9.7 μM≅1%O2. Also see Eq. (A6). (C) [HIF1α]hydroxylated:[PHD2] ratios
as a function of kSC. (D) [HIF1α]hydroxylated:[PHD2] ratios as a function of kSC, for varying values of PHD2:HIF1α synthesis rates. (E) Relative [HIF1α]unhydroxylated over 3 days
of hypoxia. Three models are compared: O2 depletion as a function of succinate (shown for a representative kSC value of 0.001 min
−super 1); PHD2 hydroxylation production
inhibition by succinate, with initial concentration ratio of [SC]0:[PHD2]0=500; and the model with synthesis and the assumption of no succinate effects.
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effect of succinate production inhibition on the hydroxylation
reaction, where HIF1α synthesis and HIF1-dependent PHD2
synthesis are present, beginning after 3 and 4 h, respectively. At
[SC]0=0.05 μM, a distinct change in [HIF1αhydroxylated]:[PHD2]occurs, shortly following the onset of PHD2 synthesis (Fig. 5A).
The relative amount of PHD2 synthesized compared to HIF1α
determines whether this change is an increase or decline (Fig. 5A).
At this concentration of succinate, a maximum or minimum in
[HIF1α]hydroxylated:[PHD2] is reached without the presence of a
1521A.A. Qutub, A.S. Popel / Biochimica et Biophysica Acta 1773 (2007) 1511–1525pronounced peak. At higher initial succinate concentrations, a
prominent peak arises for the same PHD2 to HIF1α synthesis
rates; an example is shown in Fig. 5, where [SC]0=5000 μM, a
maximum concentration used in vitro assays to mimic conditions
of SDH deficiency [23]. Looking at [HIF1α]unhydroxylated alone
shows how an initial succinate concentration of 5000 μM can
delay the peak accumulation of HIF1α by days (Fig. 5C). During
the depicted chronic hypoxia (1% O2), free PHD2 is being bound
by increasing concentrations of unhydroxylated HIF1α as well as
succinate.
3.3. Succinate affecting hydroxylation, without PHD2 product
inhibition
Succinate accumulation could possibly trigger a change in
hydroxylation by signaling a change in TCA cycle and need for
oxygen, independent of product inhibition and through an
unknown mechanism. One way of modeling this potential change
is by altering the oxygen availability as a function of succinate
production, and introducing the kinetic term kSC (Eq. (A6)). Fig. 6
shows the potential effect of succinate, where it acts not by product
inhibition, but as a distinct low oxygen signaling molecule. Using
initial values of [SC]0=0.05[PHD2]0, the effect on hydroxylation
by changing kSC appears minimal (Fig. 6A). Corresponding
changes in oxygen are shown for these kSC values (Fig. 6B).
However, when the PHD2:HIF1α synthesis rate ratio and the
dependency of the rates on oxygen is varied, the effect of succinate
as an oxygen signaling molecule is profound. For all increasing
PHD2:HIF1α synthesis ratios where there was succinate product
inhibition, the fraction of [HIF1α]hydroxylated:[PHD2] continually
decreased (Fig. 5A and B). Where succinate is represented as a
distinct low oxygen signaling molecule, changing values in the
PHD2 and HIF1α synthesis rates can alter the response to suc-
cinate. This is achieved by altering the C1 constant (from Table 3,
Case 3) as shown in Fig. 6C, or the PHD2:HIF1α synthesis ratios
(Fig. 6D). For a C1 value of 0.1, a kSC term above 10
−4 leads to a
peak of [HIF1α]hydroxylated:[PHD2] at 4 h, whereas kSC values
below, this show [HIF1α]hydroxylated:[PHD2] reaching a gradual
maximum near 8 h (Fig. 6C). For a 0.1:0.1 ratio of PHD2:HIF1α
synthesis the greatest fraction of [HIF1α]hydroxylated:[PHD2] is at
4 h for all kSC terms; ratios below or above this value lead to peak
that is dependent on kSC values (Fig. 6D). The [HIF1α]hydroxylated:
[PHD2] values eventually reach a steady-state under all conditions.
The effect of the oxygen depletionmodel on the relative amount
of unhydroxylatedHIF1α is notable. Compared to synthesis alone,
it leads to a more pronounced, earlier peak whereas increasing
succinate concentrations in the product inhibition model dampens
any oscillations and attenuates peaks in HIF1α expression (Fig. 6E
and Supplemental Fig. 3).
3.4. Adaptation and maladaptation to prolonged hypoxia
Another benefit of the computational model is that situations of
specific knockouts can be explored,where theymay be impossible
or difficult in vivo. Here we tested the effects on adaptation to
chronic hypoxia from very high PHD2:HIF1α synthesis ratios
(Fig. 3A and B), HIF1α synthesis alone (data not shown), andindependent alternations in succinate concentrations ([Fig. 4]). In
chronic hypoxic conditions, if PHD2 is not synthesized and there is
no succinate product inhibition, the accumulation of unhydroxy-
lated HIF1 would be continuous. However, succinate as product
inhibitor or a hypoxic signaling molecule may alter the effect of
overproduction of HIF1α vs. PHD2 production (Fig. 6E and
Supplemental Fig. 3).
4. Discussion
Chronic hypoxia is found in prolonged exercise, and disease
conditions, including cancer, ischemia and chronic infection. Here
we show how three compound feedback loops present in hypoxic
conditions can determine the extent of HIF1α hydroxylation, after
exposure tomore than 3 h of low oxygen levels. Combined HIF1α
synthesis, PHD2 synthesis, and succinate product inhibition
dictate the relative protein levels of HIF1α present in a cell, and
regulate a robust response to hypoxia. This response, which lowers
the relative HIF1α after 6 to 8 h (Figs. 3A and 6E; Supplemental
Fig. 3) allows adaptation to hypoxia and readies the system for a
rapid response to acute hypoxic stimulus.
Several hypotheses exist as to how succinate, and its oxidizing
enzyme, succinate dehydrogenase (SDH, also known as mito-
chondria complex II in electron transport), affect adaptation to
chronic hypoxia. One possibility is through the accumulation of
reactive oxygen species (ROS) when mitochondria complexes are
damaged (e.g., by a SDH mutation). Another theory is that a
blocked TCA cycle leads to succinate accumulation, which de-
creases the PHD2 hydroxylation reaction [23,33,54]. Both
mechanisms could lead to stabilization of the HIF1α protein and
accumulation ofHIF1 [54–56]. Here we showed succinate's effect
on product inhibition in the hydroxylation reaction ([Fig. 4]).
Succinate levels, as measured by succinate dehydrogenase
inhibition, affect HIF1α hydroxylation without the presence of
redox stress [54], which complements a model of succinate prod-
uct inhibition. Some studies have also shown that mitochondrial
electron-transfer pathways are not needed to induce HIF1
activation or oxygen sensing [57].
On the other hand, a number of alternate hypotheses merit
discussion. Hypoxic response has been shown in some studies to
involve mitochondrial electron chain complexes [58], reactive
oxygen species [59], and signaling through nitric oxide pathways
[60]. Mitochondrial respiration and electron transfer change may
limit the availability of oxygen for the PHDs [61]; however,
oxidative phosphorylation has not been shown necessary for
stabilization of HIF1α in hypoxia [56]. While other antioxidants
show no effect on HIF1α stabilization, antioxidants that scavenge
H2O2 prevent the stabilization of HIF1α in hypoxia [56,61]. How
H2O2 inhibits HIF1α degradation remains unknown — possibil-
ities include activating src kinases [55], or interfering with the
redox state of iron [30,62]. Additionally, as succinate is a part of the
TCA cycle, metabolic changes present in conditions like cancer,
ischemia and prolonged exercise, may alter the relative levels of
succinate, as well as affect pH. Further complicating analysis of the
mechanism of intracellular oxygen sensing in hypoxia, nitric oxide
may suppress HIF1α in hypoxic conditions (by damaging the
mitochondria and leading to the release of iron and 2OG into the
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cause an increase in HIF1α due to competition with oxygen [63].
Limitations of the model in resolving conflicting experimental
data should bementioned. It is one hypothesis that succinateworks
as a product inhibitor [6,23,33,53]. Other studies have shown that
TCA intermediates pyruvate and oxaloacetate bind to the 2-
oxoglutarate site on the prolyl hydroxylases and inactivate HIF1α
hydroxylation, whereas succinate does not have the same
inactivation effect [64]. The possibility remains that the response
to succinate accumulation may involve mechanisms indirectly
related toHIF1α hydroxylation, as a different signal of the absence
of the TCA cycle and need for increased oxygen [33]. The model
showed that this alternate mechanism, acting through a decrease in
oxygen as a function of succinate concentration, could have a
similar effect as the succinate product inhibition on restabilizing
the amount of hydroxylatedHIF1α relative to PHD2 concentration
(compare Fig. 5A and B with Fig. 6C and D). For the conditions
used in the model, the former mechanism showed a more rapid
stabilization of [HIF1α]unhydroxylated, for each PHD2:HIF1α syn-
thesis ratio (Fig. 6E and Supplemental Fig. 3). Where PHD2 and
HIF1α relative concentrations can be measured, this latter
observation warrants experimental testing, in an effort to confirm
one mechanism of succinate's effects.
Carbon dioxide, like succinate, is also a by-product of prolyl
hydroxylation of HIF1α, formed from the reaction with 2-
oxoglutarate (Eq. (A)). We leave the effect that the small changes
in CO2 concentration may have for future exploration; the overall
hydroxylation reaction would also be altered by intracellular
bicarbonate and pH levels, whose effects on the HIF1 pathway
have been experimentally variable [65]. Also, the model incor-
porates the reaction of 2-oxoglutarate to form succinate, without
hydroxylation, by altering the levels of succinate, availability of
free iron, and the rate of hydroxylation; as relative kinetic rates
become available, this reaction will be modeled independently.
Succinate was chosen as a focus for this study, as it is a product
of the PHD hydroxylation reaction; its dysregulation has been
studied experimentally in relation to hypoxic response and cancer
[23,60,66,67]; and SDH forms complex II of the electron transport
chain. Fumarate is another TCA cycle intermediate, a product of
succinate reactingwith SDH. Fumarate affects theHIF1α pathway
by competing with 2-oxoglutarate, parallel to one known mecha-
nism of succinate's activity [68,69]. Like succinate dehydrogenase
deficiency, fumarate hydratase deficiency has been shown to lead
to pseudohypoxic conditions, where HIF1α is elevated in
normoxia. Both TCA enzymes have important roles in the HIF1
pathway in certain conditions, and the incorporation of fumarate as
an inhibitor of PHD2 hydroxylation merits future studies.
Across cell lines, the robustness of the HIF1-dependent PHD2
feedback loop holds. The question arises, why would a positive
feedback (HIF1α synthesis) and a negative feedback (PHD
synthesis) on HIF1α expression be induced by the same stimuli
(hypoxia)? There are several possibilities. Different PHD isoforms
are induced by chronic hypoxia to various degrees [1,5], and
PHD1–3 isoforms are present in different cell types at varied levels
[32]. The large range of PHD2 expression profiles and hypoxic
response via HIF1α expression depicted in the model may be well
suited to responding to the degree and variety of hypoxic levels inthe dynamic in vivo environment. A similar rationale may be
applied to the use of succinate as a secondary negative feedback on
hydroxylation. If succinate works by product inhibition, elevated
succinate levels lead to a very distinct spike in HIF1α levels during
chronic hypoxia (Fig. 6E and Supplemental Fig. 3). This effect on
HIF1 expressionmay be of use during altered states of metabolism
or malfunction of mitochondria where succinate is accumulating,
to trigger a swift activation of the HIF1-regulated genetic cascade.
The O2 depletion model of succinate hints at an alternate
mechanism that may accentuate a pronounced cyclic course of
HIF1α (and relative PHD2 expression [6]) found during chronic
hypoxia. A self-perpetuating balance between HIF1α synthesis
and HIF1α degradation could make the system particularly
sensitive to small alterations in oxygen levels. Adding complexity,
and perhaps a fourth feedback into the HIF1 system, HIF1α has
been implicated in the down-regulation of SDH, which in turn
would increase succinate production and potentially block hydrox-
ylation of HIF1α [70]. For therapeutic applications, it may be
useful to explore (and perhaps exploit) the oscillations the model
results show in [SC]:[PHD2] ratios in normoxia (Fig. 3B), as well
as the effect of succinate on long-term hypoxia (Figs. 5 and 6;
Supplemental Fig. 3).
Targeting HIF1α [71], PHD2 [72] and metabolites [68,73]
therapeutically have become increasingly attractiveways ofmanip-
ulating cellular hypoxic response in diseases such as critical limb
ischemia and cancer. These diseases involve chronic hypoxia,
where the time course of HIF1α expression differs from transient
conditions. Experimentally it has been observed that HIF1α
regulates itself, and PHD2 is regulated by HIF1, during chronic
hypoxia. Here we developed a computational model representing
these mechanisms that is able to predict the temporal expression of
HIF1α during chronic hypoxia (Fig. 1B). Results show how and
when the ratio of HIF1α:PHD2 synthesis has its greatest effect on
HIF1α expression (Fig. 3A and C). These predictions highlight the
underlying mechanism of HIF1α expression; and by exploring a
range of relative synthesis ratios, the model anticipates effects of
therapeutically manipulating one or both compounds.
We also represented effects of the metabolite succinate on
HIF1α expression. We showed how interconnected feedback
loops involving HIF1α, PHD2, and succinate together regulate a
robust cellular response to hypoxic exposure of more than several
hours. Understanding the mechanisms underlying how intracellu-
lar processes respond to chronic hypoxia and metabolic changes
provide insight into adaptation processes. The model suggests that
during days of hypoxia where there is no SDH deficiency, likely
what occurs are cyclic changes in HIF1α levels, as PHD2 and
HIF1α levels dynamically alter and counterbalance each other
(Fig. 5E). Where there is SDH deficiency or a mitochondrial
defect, if succinate inhibits hydroxylation, this cyclic expression
would be dampened (Fig. 6E and Supplemental Fig. 3). In com-
parison, for shorter-term chronic hypoxia, such as during
endurance exercise, the model represents a steep increase in
HIF1α between 4 and 8 h and then leveling off to a new level of
HIF1α (Fig. 3A and C), in agreement with experiments and
support of the hypothesis that the mechanism underlying hypoxic
preconditioning involves PHD2. These results give fundamental
rationale for therapeutic design altering the HIF1 pathway, in a
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account metabolic conditions.
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Appendix A. Governing equations
Overall reaction sequence, incorporating the assumptions of
pseudo-steady-state and bidirectionality in the binding of prolyl
hydroxylase with iron, 2-oxoglutarate, oxygen and ascorbate;
assumptions of pseudo-steady-state and product inhibition by
succinate in the hydroxylation of HIF1α; production ofHIF1α and
prolyl hydroxylase; and reversibility in the ubiquitination of
hydroxylated HIF1α by the VHL complex:Parameter Abbreviation
(PHD2·Fe2+·
2OG·O2·Asc)O2 splitPHD2 enzyme, following hydroxylation O2 split refers
to PHD2 using oxygen to hydroxylate HIF1α while
simultaneously oxidizing 2OG to succinate(A)Table 1 gives abbreviations. The 17 differential equations
representing hydroxylation and ubiquitination of HIF1α were
defined previously by Eqs. (10) through (26) of reference [30].
The assumption of pseudo-steady-state and bidirectionality in
the binding of prolyl hydroxylase with iron, 2-oxoglutarate,
oxygen and ascorbate were justified by experimental observa-
tions [76–79]. These binding reactions were assumed to follow
Michaelis–Menten like kinetics, without intermediates being
formed. The relationship between koff and kon, could then be
approximated by:
KmcKD ¼ koffkon
The final step in the series of PHD2 binding is assumed
irreversible for the hydroxylation of HIF1α by the PHD2 complex
without ascorbate, PHD2·Fe2+·2OG·O2, and with minimal revers-
ibility for hydroxylation by the PHD2 complex with ascorbate,
PHD2mod=PHD2·Fe
2+·2OG·O2·Asc, as defined by koff,HIF1α
(without consideration of SC) or k′off,HIF1α (with SC considered).
Here we present modified equations for the mass balances of
PHD2, HIF1α, and PHD2mod·HIF1α (Eqs. (11), (19) and (20) in
reference [30]), incorporating the synthesis terms defined in Table
3. We also introduce the compound succinate, and represent two
possible mechanisms of its interactions in the HIF1α pathway. In
the model, succinate is included by an equation describing its
concentration change with time for the case of production
inhibition (Eq. (A5)) or by its effects on signaling oxygen
availability (Eq. (A6)). Expect for when O2 changes are a functionof SC, changes inO2 andCO2 as a result of theHIF1α reactions are
assumed to be negligible.
A.1. Reactions of PHD2
d½PHD2
dt
¼ koff ;Fe2þ PHD2dFe2þ
 
 kon;Fe2þ PHD2½  Fe2þ
 
þ kcat;Fe2þ PHD2dFe2þ
 þ qprod;PHD2 ðA1Þ
Case 1, for all tN tPHD2:
qprod;PHD2 ¼ kprod;PHD2dqprod;HIF1a ðA1:1Þ
Case 2, qprod,PHD2 is defined distinctly for different times:for
tN tPHD2 and tb24 h:
q1prod;PHD2 ¼ kVprod;PHD2ðtÞdq2prod;PHD2
¼ kVprod;PHD2ðtÞdkprod;PHD2dqprod;HIF1a ðA1:2Þ
for tN24 h:
q2prod;PHD2 ¼ kprod;PHD2dqprod;HIF1a ðA1:3Þ
Case 3 (default), for all tN tPHD2:
qprod;PHD2 ¼ kprod;PHD2dqprod;HIF1a
A.2. Reaction of PHD2·Fe2+·2OG·O2·Asc (PHD2mod) andHIFlα
Note for reactions (A2) and (A3), these equations were
modified to allow reaction with an intermediate uncoupled to Asc.
d½HIF1a
dt
¼ k Voff ;HIF1a PHD2moddHIF1a½  SC½ 
 kon;HIF1a PHD2mod½  HIF1a½ 
 kon;HIF1a PHD2dFe2þd2OGdO2
 
HIF1a½ 
þ qprod;HIF1a ðA2Þ
Cases 1 and 2, for all tN tHIF1α:
qprod;HIF1a ¼ kprod;HIF1ad ½O2ð½O2 þ C2Þ ðA2:1Þ
Case 3, for all tN tHIF1α:
qprod;HIF1a ¼ k Vprod;HIF1ad
½O2d½HIF1a
ð½HIF1a þ C1d½O2Þ ðA2:2Þ
d½PHD2moddHIF1a
dt
¼ kon;HIF1a PHD2mod½  HIF1a½ 
þ kon;HIF1a½PHD2dFe2þd2OGdO2
½HIF1a
 k Voff ;HIF1a PHD2moddHIF1a½  SC½ 
 kcat;HIF1a PHD2moddHIF1a½ 
ðA3Þ
d½HIF1ah
dt
¼ kcat;HIF1a PHD2moddHIF1a½  ðA4Þ
1524 A.A. Qutub, A.S. Popel / Biochimica et Biophysica Acta 1773 (2007) 1511–1525A.3. Reaction of SC productiond½SCA.4. Change in O2 levels as a function of SC (equation used for
Fig. 6) O2 reaction binding terms remain as in [30]
d½O2
dt
¼ kSC SC½  ðA6Þ
Appendix B. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.bbamcr.2007.07.004.
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